| 陈良敏,江 咏,邢丽娟,王 晶,褚志华,高 谨,李建强.依那西普联合来氟米特治疗强直性脊柱炎的疗效观察及安全性分析[J].,2017,17(22):4292-4294 |
| 依那西普联合来氟米特治疗强直性脊柱炎的疗效观察及安全性分析 |
| The Efficacy of Etanercept Combined Leflunomide to Treat Ankylosing Spondylitis and Its Safety |
| 投稿时间：2016-11-12 修订日期：2016-11-30 |
| DOI：10.13241/j.cnki.pmb.2017.22.021 |
| 中文关键词: 依那西普 来氟米特 强直性脊柱炎 疗效 安全性 |
| 英文关键词: Etanercept Leflunomide Ankylosing spondylitis Efficacy Safety |
| 基金项目: |
|
| 摘要点击次数: 291 |
| 全文下载次数: 215 |
| 中文摘要: |
| 摘要 目的：探究依那西普联合来氟米特治疗强直性脊柱炎（AS）的疗效及安全性。方法：收集2015年1月-2016年6月间我院收治的AS患者90例，按随机数字表法分为观察组和对照组，每组各45例。观察组采用依那西普联合来氟米特治疗，对照组则单纯采用来氟米特治疗。记录两组治疗前后的晨僵时间、AS活动性指数（BASDAI）和AS测量指数（BASMI），比较两组治疗总有效率及不良反应发生情况。结果：治疗后，两组患者晨僵时间、BASDAI及BASMI较治疗前均有所下降，且观察组上述各指标均显著低于对照组，差异有统计学意义（P＜0.05）；观察组总有效率显著高于对照组，差异有统计学意义（P＜0.05）；治疗过程中，患者发生的主要不良反应为肝功能损伤、腹泻和过敏性皮疹，但两组不良反应发生率差异无统计学意义（P＞0.05）。结论：依那西普联合来氟米特可获得比较理想的疗效，且不良反应发生率较低，值得在临床上推广使用。 |
| 英文摘要: |
| ABSTRACT Objective: To explore the efficacy of etanercept combined leflunomide to treat ankylosing spondylitis (AS) and its safety. Methods: 90 cases with AS patients admitted in our hospital from June 2016 to January 2015 were selected. The patients were divided into observation group and control group by random number table method, 45 cases in each group. Observation group was treated with etanercept combined with leflunomide, the control group were treated by leflunomide only. Morning stiffness time, AS activity index (BASDAI), AS measurement index (BASMI) were recorded before and after treatment in two groups, the total effective rate and adverse reaction were compared between the two groups. Results: After treatment, the BASDAI and morning stiffness time, BASMI of two groups of patients compared with before treatment were decreased, and the indexes above of the observation group were significantly lower than the control group, the difference was statistically significant(P<0.05); The effective rate of the observation group was significantly higher than that of the control group, the difference was statistically significant(P<0.05); During the course of treatment, the main adverse reactions occurred in patients with liver function damage, diarrhea and allergic skin rash,but there was no significant difference in the incidence of adverse reactions between the two groups (P>0.05). Conclusion: Etanercept combined with leflunomide can obtain ideal effect, and low incidence rate of adverse reaction, it is worth popularizing in clinical use. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
